Continued Itacitinib Treatment for Myelofibrosis
Trial Summary
What is the purpose of this trial?
This trial provides the medication itacitinib to participants from previous studies who may benefit from continued treatment. Itacitinib helps reduce inflammation by blocking specific proteins that cause it.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, since this study is a continuation of previous itacitinib treatment, it is likely that you can continue your current regimen if it was part of the original study.
What data supports the effectiveness of the drug itacitinib for myelofibrosis?
Itacitinib is a JAK1 inhibitor, similar to ruxolitinib, which is a JAK1/2 inhibitor that has shown effectiveness in treating myelofibrosis by reducing symptoms like enlarged spleen and improving quality of life. While specific data on itacitinib for myelofibrosis is not provided, the success of similar JAK inhibitors suggests potential benefits.12345
How does the drug itacitinib differ from other treatments for myelofibrosis?
Itacitinib is a JAK1 inhibitor, which may offer a different approach compared to existing JAK2 inhibitors like ruxolitinib, the current standard treatment for myelofibrosis. This difference in targeting could potentially lead to varied effects on symptoms and side effects, providing an alternative for patients who may not respond well to JAK2 inhibitors.23678
Research Team
Lance Leopold, MD
Principal Investigator
Incyte Corporation
Eligibility Criteria
This trial is for patients already taking itacitinib in other Incyte-sponsored studies, who are benefiting and tolerating the treatment well. They must understand and agree to study procedures, avoid pregnancy or fathering children, and not have any illness that could risk their safety or study compliance.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive continued treatment with itacitinib as per the treatment dose and schedule from their original study
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- itacitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Incyte Corporation
Lead Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School